Assessment cycle 2023 Q1 — page 13
Documents ratified in the 2023 Q1 assessment cycle, which ran from 1 January 2023 to 31 March 2023 and was ratified on 18 March 2023.
Documents ratified
-
Randomised crossover, phase 1 study of Semaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low09 Jan 2024 -
Phase 1 ascending dose, phase 1 study of Semaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low16 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The…
Very low13 Jul 2023 -
Single-arm open-label, phase 3 study of Tirzepatide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low08 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low26 Aug 2023 -
Randomised crossover, phase 1 study of Liraglutide in prediabetes and obesity over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low11 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in sleep apnoea and obesity over as stated in the parent protocol. The Institute holds no…
Very low12 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in adolescent obesity over as stated in the parent protocol. The Institute holds no reported…
Very low16 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low12 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low06 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low06 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low10 Jul 2023 -
Phase 1 ascending dose, phase 1 study of Dulaglutide in type 2 diabetes and chronic kidney disease over as stated in the parent protocol. The Institute holds no reported…
Very low09 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low20 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low23 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low09 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low01 May 2023 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low02 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low14 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low27 Jan 2024 -
Observational, phase 3 study of PT-141 (bremelanotide) in sexual dysfunction over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low19 Feb 2024 -
Observational, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result…
Very low18 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low03 Nov 2023 -
Randomised crossover, phase 1 study of Liraglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low15 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Liraglutide in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low08 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low26 Apr 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cardiovascular over as stated in the parent protocol. The Institute holds no reported primary…
Very low14 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tesamorelin in lipodystrophy over as stated in the parent protocol. The Institute holds no reported…
Very low17 Apr 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Tesamorelin in mash over as stated in the parent protocol. The Institute holds no reported primary result…
Very low13 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ipamorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary…
Very low01 Aug 2023 -
Phase 1 ascending dose, phase 1 study of Ipamorelin in gastric emptying over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low03 Dec 2023 -
Single-arm open-label, phase 1 study of CJC-1295 in gh axis over open-label extension of the parent trial. The Institute holds no reported primary result for this record…
Very low23 Jan 2024 -
Single-arm open-label, phase 1 study of Hexarelin in gh axis over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low10 May 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Hexarelin in lean-mass preservation over as stated in the parent protocol. The Institute holds no reported…
Very low23 Jul 2023 -
Phase 1 ascending dose, phase 1 study of GHRP-2 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low12 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 1 study of GHRP-6 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low30 Sep 2023 -
Randomised crossover, phase 1 study of AOD-9604 in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low05 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of AOD-9604 in knee osteoarthritis over as stated in the parent protocol. The Institute holds no reported…
Very low05 May 2023
page 13 of 13